🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of the Impact of Phosphate Supplementation on FGF23 Concentrations in Patients With Hypophosphatemia

RecruitingNAAges 18 Years - anyAllUniversity Hospital, Clermont-Ferrand
NCT07827989 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Fibroblast growth factor 23 (FGF23) is the principal hormone regulating serum phosphate homeostasis. Secreted by osteocytes, it promotes renal phosphate excretion and suppresses the synthesis of 1,25-dihydroxyvitamin D. Measurement of FGF23 has become a key tool in the evaluation of hypophosphatemia, allowing distinction between FGF23-dependent forms (such as X-linked hypophosphatemic rickets, tumor-induced osteomalacia, and intravenous iron-induced hypophosphatemia) and FGF23-independent forms (including renal, gastrointestinal, nutritional, or drug-related causes). In healthy adults, several studies have demonstrated that FGF23 levels vary according to phosphate intake, decreasing during dietary restriction and increasing following phosphate loading. In hypophosphatemic conditions, however, available data are limited to X-linked hypophosphatemic rickets, where prolonged supplementatio

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients hospitalized in adult intensive care, oncology, or rheumatology * Hypophosphatemia \< 0.8 mmol/L * Clinical indication for phosphate supplementation Exclusion Criteria: * Chronic kidney disease, stage ≥ 3 (eGFR \< 60 mL/min/1.73 m²) * Treatment with Ferinject® within the past year * Sepsis * Current treatment with active vitamin D * Pregnancy or breastfeeding * Inability to perform blood draws due to insufficient venous access * Weight \< 35 kg (for intensive care patients only) * Hypercalcemia \> 2.6 mmol/L
💊

What it tests

  • Blood sample
📍

Where

3 sites
CHU Clermont-Ferrand Service de réanimation
Clermont-Ferrand, France
CHU Clermont-Ferrand Service Oncologie
Clermont-Ferrand, France
CHU Clermont-Ferrand Service Rhumatologie
Clermont-Ferrand, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy